Anti-aging food composition as well as preparation method and application thereof

Abstract

The invention discloses an anti-aging food composition as well as a preparation method and application thereof, and belongs to the technical field of functional foods. The anti-aging food composition is prepared from the following raw material components in parts by weight: 40 to 60 parts of rhizoma polygonati powder, 15 to 30 parts of green tea theanine, 1 to 3 parts of sea cucumber oligopeptide powder, 0.5 to 1.5 parts of spearmint extract and 0.2 to 0.4 part of pyrroloquinoline quinone disodium. The anti-aging food composition provided by the invention has a positive regulation effect on related indexes causing aging, has no obvious influence on the body weight, food intake and internal organ indexes of aged mice, and has relatively good safety. The anti-aging food composition provided by the invention has the characteristics of few components, low cost, good action effect and high safety, and is suitable for the development of anti-aging functional foods.

Description

Technical Field

[0001] The present invention belongs to the technical field of functional foods, and particularly relates to an anti-aging food composition, a preparation method thereof, and an application thereof. Background Art

[0002] Aging is a complex biological process, accompanied by the gradual decline of various physiological functions, such as decreased metabolic capacity, weakened immune function, and reduced cognitive function. These changes increase the risk of diseases in the elderly. Functional foods, with their rich bioactive components, provide a new strategy for delaying aging.

[0003] Chinese invention patent CN103300382B discloses an anti-aging collagen peptide nutrient, which is made from the following raw materials in weight percentages: 4%-6% of sea cucumber extract, 4%-6% of vitamin C, 5%-7% of seaweed extract, 5%-7% of glucosamine hydrochloride, trace selenium, and the balance is long-acting oligopeptide collagen, with a total of 100%; the dosage of selenium is 0.02-0.03 g / kg. Using long-acting oligopeptide collagen instead of ordinary collagen has better absorption and a longer action time on the human body, and it plays a good role in anti-aging, antioxidant, and improving immunity. However, the raw material cost in the foregoing patent is relatively high. Some Chinese medicinal materials can be both medicine and food. On the premise of ensuring the effect, the cost can be reduced. Chinese invention patent CN118749663B discloses an anti-aging functional peptide composition and a preparation method thereof, which includes the following components in parts by weight: 1-10 parts of ascorbic acid polypeptide, 10-30 parts of calcium peptide chelate, 1-10 parts of medicinal phellinus linteus polysaccharide, 10-20 parts of plant extract, 1-10 parts of bird's nest extract, 1-5 parts of sea cucumber peptide, 1-5 parts of chlorella active peptide, 1-10 parts of excipient, and 15-45 parts of water. Although the foregoing patent adds Chinese medicinal extracts, it still has the technical problems of high cost, and the foregoing composition has many components, high cost, and the effect needs to be further improved. Summary of the Invention

[0004] In order to solve the problems in the prior art, the present invention provides an anti-aging food composition, a preparation method thereof, and an application thereof. Through the synergistic effect of polygonatum sibiricum powder, L-theanine, sea cucumber oligopeptide powder, mentha spicata extract, and pyrroloquinoline quinone disodium, the composition achieves the technical effects of fewer components, lower cost, and good action effect.

[0005] The first aspect of the present invention relates to an anti-aging food composition. The raw material components of the anti-aging food composition are as follows in parts by weight: 40-60 parts of polygonatum sibiricum powder, 15-30 parts of L-theanine, 1-3 parts of sea cucumber oligopeptide powder, 0.5-1.5 parts of mentha spicata extract, and 0.2-0.4 parts of pyrroloquinoline quinone disodium.

[0006] Preferably, the raw material components of the anti-aging food composition by weight are: 40-55 parts of polygonatum sibiricum powder, 15-25 parts of L-theanine, 1-3 parts of sea cucumber oligopeptide powder, 0.5-1.2 parts of mentha spicata extract, and 0.25-0.4 parts of pyrroloquinoline quinone disodium.

[0007] Preferably, the raw material components of the anti-aging food composition by weight are: 50 parts of polygonatum sibiricum powder, 20 parts of L-theanine, 2 parts of sea cucumber oligopeptide powder, 1 part of mentha spicata extract, and 0.3 parts of pyrroloquinoline quinone disodium.

[0008] More preferably, the weight ratio of the polygonatum sibiricum powder to the L-theanine is 1-3:1.

[0009] More preferably, the weight ratio of the sea cucumber oligopeptide powder, the mentha spicata extract to the pyrroloquinoline quinone disodium is 5-8:3-4:1.

[0010] The second aspect of the present invention relates to a preparation method of the above anti-aging food composition. The preparation method is: weighing each raw material component by weight, mixing evenly, and then obtaining the product.

[0011] The third aspect of the present invention relates to a preparation containing the above anti-aging food composition.

[0012] Preferably, the preparation further includes food-acceptable excipients, and the excipients are selected from one or more of microcrystalline cellulose, hydroxypropyl cellulose, and magnesium stearate.

[0013] Preferably, the preparation is a solid beverage, a liquid beverage, a nutrition bar, a compressed candy, a pill, or a baked product.

[0014] The fourth aspect of the present invention relates to the use of the above anti-aging food composition or the anti-aging food composition obtained by the above preparation method or the preparation containing the above composition in the preparation of anti-aging products.

[0015] Preferably, the product is a health product, a functional food, or a special medical food.

[0016] Compared with the prior art, the beneficial effects that the present invention can achieve are as follows: (1) Through the synergistic effect of the components polygonatum sibiricum powder, L-theanine, sea cucumber oligopeptide powder, mentha spicata extract and pyrroloquinoline quinone disodium in the anti-aging food composition prepared by the present invention, within a certain dosage ratio range, the technical effects of less components, low cost and good action effect of the composition are achieved; (2) The composition provided by the present invention significantly reduces the aging index of aging mice, improves the muscle function of aging mice, improves the exploratory behavior and cognitive function of aging mice, has a positive regulatory effect on the indexes of aging mice, and improves the degree of aging; (3) The composition of the present invention has no significant effect on the body weight, food intake and visceral organ index of aging mice, which indicates that long-term intake of the formula sample will not cause malnutrition or abnormal weight change, and has good safety. The anti-aging food composition provided by the present invention has the technical effects of less components, low cost, good action effect and high safety. Detailed implementation manners

[0017] The present invention will be described below through examples to make the technical solutions of the present invention easier to understand and master, but the present invention is not limited thereto. The experimental methods described in the following examples are all conventional methods unless otherwise specified; the medicinal materials and reagents can be obtained from commercial channels unless otherwise specified; and the performance of products from different sources has no significant impact.

[0018] When the examples give numerical ranges, it should be understood that unless otherwise specified by the present invention, any value between the two endpoints of each numerical range and any one of the two endpoints can be selected. Unless otherwise defined, all technical and scientific terms used in the present invention have the same meaning as commonly understood by those of ordinary skill in the technical field to which the present invention belongs.

[0019] All kinds of chemical reagents and raw materials used in the examples of the present invention are obtained through conventional commercial channels unless otherwise specified, and products from different manufacturers have no significant impact on the effects.

[0020] Example 1

[0021] An anti-aging food composition, the raw material components of the anti-aging food composition by weight are: 40 parts of polygonatum sibiricum powder, 25 parts of L-theanine, 2 parts of sea cucumber oligopeptide powder, 1.2 parts of mentha spicata extract and 0.3 part of pyrroloquinoline quinone disodium.

[0022] The preparation method is: weigh each raw material component by weight, mix evenly, and obtain.

[0023] Example 2

[0024] An anti-aging food composition, the raw material components of the anti-aging food composition by weight are: 55 parts of polygonatum sibiricum powder, 15 parts of L-theanine, 3 parts of sea cucumber oligopeptide powder, 0.5 part of mentha spicata extract, and 0.4 part of pyrroloquinoline quinone disodium.

[0025] The preparation method is: weigh each raw material component by weight, mix evenly, and obtain.

[0026] Example 3

[0027] An anti-aging food composition, the raw material components of the anti-aging food composition by weight are: 50 parts of polygonatum sibiricum powder, 20 parts of L-theanine, 2 parts of sea cucumber oligopeptide powder, 1 part of mentha spicata extract, and 0.3 part of pyrroloquinoline quinone disodium.

[0028] The preparation method is: weigh each raw material component by weight, mix evenly, and obtain.

[0029] Comparative Example 1

[0030] An anti-aging food composition, the raw material components of the anti-aging food composition by weight are: 70 parts of L-theanine, 2 parts of sea cucumber oligopeptide powder, 1 part of mentha spicata extract, and 0.3 part of pyrroloquinoline quinone disodium.

[0031] The preparation method is: weigh each raw material component by weight, mix evenly, and obtain.

[0032] The difference from Example 3 is that the component does not contain polygonatum sibiricum powder, and its dosage is added to L-theanine.

[0033] Comparative Example 2

[0034] An anti-aging food composition, the raw material components of the anti-aging food composition by weight are: 70 parts of polygonatum sibiricum powder, 2 parts of sea cucumber oligopeptide powder, 1 part of mentha spicata extract, and 0.3 part of pyrroloquinoline quinone disodium.

[0035] The preparation method is: weigh each raw material component by weight, mix evenly, and obtain.

[0036] The difference from Example 3 is that the component does not contain L-theanine, and its dosage is added to polygonatum sibiricum powder.

[0037] Comparative Example 3

[0038] An anti-aging food composition, the raw material components of the anti-aging food composition by weight are: 50 parts of polygonatum sibiricum powder, 20 parts of L-theanine, 2.2 parts of sea cucumber oligopeptide powder, 1.1 parts of mentha spicata extract.

[0039] The preparation method is: weigh each raw material component by weight, mix evenly, and obtain.

[0040] The difference from Example 3 is that the component does not contain sodium pyrroloquinoline quinone disodium, and its dosage is added to the sea cucumber oligopeptide powder and the spearmint extract in proportion.

[0041] Comparative Example 4

[0042] An anti-aging food composition, and the raw material components of the anti-aging food composition by weight are: 50 parts of polygonatum sibiricum powder, 20 parts of L-theanine, 2.87 parts of sea cucumber oligopeptide powder, and 0.43 parts of sodium pyrroloquinoline quinone disodium.

[0043] The preparation method is: weighing each raw material component by weight, and mixing evenly to obtain.

[0044] The difference from Example 3 is that the component does not contain spearmint extract, and its dosage is added to the sea cucumber oligopeptide powder and sodium pyrroloquinoline quinone disodium in proportion.

[0045] Comparative Example 5

[0046] An anti-aging food composition, and the raw material components of the anti-aging food composition by weight are: 56 parts of polygonatum sibiricum powder, 14 parts of L-theanine, 2 parts of sea cucumber oligopeptide powder, 1 part of spearmint extract, and 0.3 parts of sodium pyrroloquinoline quinone disodium.

[0047] The preparation method is: weighing each raw material component by weight, and mixing evenly to obtain.

[0048] The difference from Example 3 is that the dosages of polygonatum sibiricum powder and L-theanine and their weight ratio are different. In Comparative Example 5, there are 56 parts of polygonatum sibiricum powder and 14 parts of L-theanine, and the mass ratio of the two is 4; while in Example 3, there are 50 parts of polygonatum sibiricum powder and 20 parts of L-theanine, and the mass ratio of the two is 2.5.

[0049] Comparative Example 6:

[0050] An anti-aging food composition, and the raw material components of the anti-aging food composition by weight are: 50 parts of polygonatum sibiricum powder, 20 parts of L-theanine, 1.5 parts of sea cucumber oligopeptide powder, 1.2 parts of spearmint extract, and 0.6 parts of sodium pyrroloquinoline quinone disodium.

[0051] The preparation method is: weighing each raw material component by weight, and mixing evenly to obtain.

[0052] The difference from Example 3 is that the dosages of sea cucumber oligopeptide powder, spearmint extract, and sodium pyrroloquinoline quinone disodium and their weight ratio are different. In Comparative Example 6, there are 1.5 parts of sea cucumber oligopeptide powder, 1.2 parts of spearmint extract, and 0.6 parts of sodium pyrroloquinoline quinone disodium, and the mass ratio of the three is 2.5:2:1; while in Example 3, there are 2 parts of sea cucumber oligopeptide powder, 1 part of spearmint extract, and 0.3 parts of sodium pyrroloquinoline quinone disodium, and the mass ratio of the three is 6.6:3.3:1.

[0053] Experimental Example 1: Efficacy Test

[0054] 1. The experimental materials used are shown in Table 1 below.

[0055] Table 1: Experimental Materials

[0056]

[0057] 2. Experimental Animals and Grouping

[0058] SPF-grade C57BL / 6 male mice (weighing 18 - 21 g) were purchased from Guangdong Medicilon Biotechnology Inc. (production), and the experimental animal production license number is: SCXK (Guangdong) 2020 - 0054. The experimental animals were fed in the SPF-grade experimental animal house of the Third Institute of Oceanography, Ministry of Natural Resources, and the experimental animal use license number is: SYXK (Fujian) 2019 - 0002. After the experimental animals were fed until 17 months old, they were randomly grouped according to body weight, with 10 mice in each group. They were respectively: control group, Example 1 group - Example 3 groups, Comparative Example 1 group - Comparative Example 6 groups, and the administration dose was 1 g / kg body weight. Among them, the compositions of Example 1 - Example 3 and Comparative Example 1 - Comparative Example 6 were dissolved in normal saline and shaken well before gavage. Among them, the control group was gavaged with the blank solvent, and the groups of Example 1 - Example 3 and Comparative Example 1 - Comparative Example 6 were gavaged with the corresponding composition solutions. The gavage volume was 10 mL / kg body weight, once a day for 35 consecutive days.

[0059] Use Excel 2023 software to organize the experimental data and calculate statistical parameters, and use one-way analysis of variance (One-way ANOVA) to statistically analyze the differences.

[0060] (1) Effects on the body weight and food intake of senescent mice

[0061] According to the evaluation method, record the feed intake, feed delivery amount, and remaining feed amount every day, measure the body weight of the experimental mice before the experiment and after continuous gavage administration to senescent mice for 35 days, calculate the body weight change and food intake, and the results are shown in the following table.

[0062] Table 2: Effects on the body weight and food intake of senescent mice

[0063] Group Weight change (g) Food intake (g / day / animal) Control group 34.79±0.54 3.2±0.6 Example 1 group 35.69±0.43 3.3±0.8 Example 2 group 33.92±0.68 3.5±0.9 Example 3 group 37.28±0.69 3.4±0.5 Comparative example 1 group 36.58±0.12 3.6±0.5 Comparative example 2 group 32.74±0.56 3.5±1.1 Comparative example 3 group 34.31±0.21 3.2±0.3 Comparative example 4 group 35.88±0.22 3.5±0.9 Comparative example 5 group 36.55±0.84 3.1±0.7 Comparative example 6 group 35.46±0.24 3.0±0.8

[0064] According to the changes in the body weight of the mice before and after the experiment in the table, it can be seen that: the composition of the present invention does not affect the body weight and food intake of senescent mice.

[0065] (2) Effects on the senescence index score of senescent mice

[0066] After continuously intragastrically administering the sample to senescent mice for 33 days, the senescence scores of the mice were evaluated from multiple aspects such as skin glossiness, spinal curvature, and eye lesions. The specific experimental procedure was as follows: The mice were placed in a clean cage and continuously observed for 30 seconds. They were scored according to the eight categories in Table 3 based on the degree of change. Each category had four levels corresponding to the intensity of the change. For example, level 0 represented no special change and corresponded to a score of 0 points; level 4 represented the most severe change and corresponded to a score of 3 points. That is, the total score was 24 points, and the higher the score, the more severe the senescence.

[0067] Table 3: Senescence Scoring Index for Mice

[0068]

[0069] The senescence index scoring results of each group are shown in Table 4.

[0070] Table 4: Senescence Index Scoring Results

[0071]

[0072]

[0073] Note: Compared with the control group, between each sample-administered group & indicates P < 0.05, && compared with the group of Example 3, between each sample-administered group # indicates P < 0.05, ## indicates P < 0.01.

[0074] Compared with the control group, each sample-administered group could reduce the senescence index score of senescent mice. However, compared with the group of Example 3, the effects of each comparison group were inferior to those of the Example group, and the anti-senescence effect of the sample composition in the examples of the present invention was more significant.

[0075] (3) Effect on the muscle strength of senescent mice

[0076] After continuously intragastrically administering the sample to senescent mice for 33 days, the grasping force of each group of mice was detected using a UGO-47200 grasping force tester. The experimental procedure was as follows: Using the UGO-47200 grasping force tester, the grasping force of the limbs of each group of mice was detected. The grasping force range was set to 0 - 500 g. After the instrument was automatically calibrated, the mouse's tail was grasped, and it was gently placed horizontally in the center of the grasping grid plate and moved backward until it separated from the grid plate. The peak grasping force was recorded, and each mouse was continuously measured three times. The specific results are shown in the following table.

[0077] Table 5: Results of the Effect on the Grasping Force of Senescent Mice

[0078]

[0079]

[0080] Note: Compared with the control group, among the sample - given groups & indicates P < 0.05, && indicates P < 0.01; compared with the group of Example 3, among the sample - given groups # indicates P < 0.05.

[0081] According to the data in the table, each sample - given group can improve the grasping force of senescent mice. However, compared with the group of Example 3, the effect of each comparative group is inferior to that of the Example group. The sample composition of the embodiment of the present invention has a better effect of improving the muscle function of senescent mice.

[0082] (4) Detection of behavior in the open - field

[0083] After continuously intragastrically administrating the sample to senescent mice for 34 days, an animal behavior analysis system was used to detect the behavioral performance of mice in the open - field. The specific process was as follows: Before the experiment, the mice were placed in the experimental environment 1 hour in advance to reduce the stress response to the new environment. During the formal experiment, the mice were gently placed in the central area of the pre - adjusted open - field device, and their behaviors in the open - field for 5 - 10 minutes were recorded, including the staying time in the center of the open - field and the walking distance in the central area, etc. The whole experiment process needed to be kept quiet. After the experiment, the behavioral patterns of each group of mice were statistically analyzed according to the video recording and the data analysis of the animal behavior video analysis system. The results are shown in the following table.

[0084] Table 6: Results of the influence on the behavior of senescent mice

[0085] Group Stay time in the middle of the mine (s) Walking distance in the middle area of the mine (mm) Control group 4.8±2.2 329.5±67.9 Example 1 group <![CDATA[14.3±5.1 && > <![CDATA[511.4±113.2 & > Example 2 group <![CDATA[13.9±4.6 && > <![CDATA[501.6±116.4 & <!-- 7 -->]]> Example 3 group <![CDATA[14.1±4.9 && > <![CDATA[508.1±111.5 & > Comparative example 1 group <![CDATA[8.2±3.1 &# > <![CDATA[403.4±79.6 &&# > Comparative example 2 group <![CDATA[8.9±3.4 &# > <![CDATA[411.9±81.2 &&# > Comparative example 3 group <![CDATA[9.1±3.3 &# > <![CDATA[415.7±82.6 &&# > Comparative example 4 group <![CDATA[8.7±3.5 &# > <![CDATA[408.6±80.7 &&# > Comparative example 5 group <![CDATA[10.6±3.8 &# > <![CDATA[453.4±83.8 &&## > Comparative example 6 group <![CDATA[10.9±4.1 &# > <![CDATA[451.7±80.4 &&## >

[0086] Note: Compared with the control group, among the sample - given groups & indicates P < 0.05, && indicates P < 0.01; compared with the group of Example 3, among the sample - given groups # indicates P < 0.05, ## indicates P < 0.01.

[0087] It can be seen from the table that compared with the control group, the administration group significantly increased the staying time and the walking distance in the middle area of senescent mice in the open - field. However, compared with the group of Example 3, the effect of each comparative group is inferior to that of the Example group. The composition of the present invention is more helpful for improving the exploratory behavior and possible cognitive function of senescent mice, and at the same time can improve the activity ability of senescent mice, and promote their motor coordination and physical strength.

[0088] (5) Influence on the liver function of senescent mice

[0089] After 35 days of intragastric administration of the sample to mice, the mice were fasted for 12 hours and then blood was collected from the inner canthus of the orbit. Serum was obtained after centrifugation. The levels of serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in each group were detected by an automatic biochemical analyzer (Mindray BS-240VET). The results are shown in the following table.

[0090] Table 7: Effects on the liver function of aging mice

[0091] Group ALT (U / L) AST (U / L) Control group 38.24±3.39 181.22±30.51 Example 1 group <![CDATA[19.52±2.88 && > 176.94±33.47 Example 2 group <![CDATA[20.11±2.34 && > 178.22±34.69 Example 3 group <![CDATA[19.13±2.04 && > 183.43±32.11 Comparative example 1 group <![CDATA[28.26±2.61 &# > 182.56±35.22 Comparative example 2 group <![CDATA[27.87±2.46 &# > 184.77±33.26 Comparative example 3 group <![CDATA[29.96±2.39 &# > 181.99±31.74 Comparative example 4 group <![CDATA[26.12±2.28 &# > 180.95±32.27 Comparative example 5 group <![CDATA[22.84±2.27 &# > 199.43±33.48 Comparative example 6 group <![CDATA[22.99±2.04 &# > 181.92±32.64

[0092] Note: Compared with the control group, between each sample-administered group & indicates P < 0.05, && indicates P < 0.01; compared with the group of Example 3, between each sample-administered group # indicates P < 0.05.

[0093] It can be seen from the above results that compared with the control group, after administration of the sample, the ALT activity can be significantly reduced, but the effects of Examples 1 - 3 are better than those of Comparative Examples 1 - 6. The samples of Examples 1 - 3 of the present invention have a better liver protection effect on aging mice.

[0094] (6) Effects on serum lipid metabolism

[0095] The mice were intragastrically administered with the formulated sample for 35 days, then blood was collected from the orbit after fasting for 12 hours, and serum was obtained after centrifugation. The contents of total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) in the serum of each group were detected by an automatic biochemical analyzer (Mindray Medical). The results are shown in the following table.

[0096] Table 8: Effects on serum lipid metabolism (unit: mmol / L)

[0097] Group TC TG HDL-C LDL-C Control group 3.87±0.19 0.86±0.08 2.21±0.31 0.24±0.06 Example 1 group 3.86±0.22 <![CDATA[0.61±0.14 && > 2.51±0.38 <![CDATA[0.16±0.03 && > Example 2 group 3.69±0.14 <![CDATA[0.63±0.18 && > 2.64±0.49 <![CDATA[0.17±0.09 && > Example 3 group 3.55±0.17 <![CDATA[0.59±0.15 && > 2.23±0.24 <![CDATA[0.16±0.12 && > Comparative example 1 group 3.85±0.23 <![CDATA[0.72±0.13 &# > 2.75±0.32 <![CDATA[0.21±0.10 ## > Comparative example 2 group 3.68±0.20 <![CDATA[0.76±0.17 &# > 2.74±0.39 <![CDATA[0.19±0.03 &# > Comparative example 3 group 3.96±0.24 <![CDATA[0.73±0.16 &# > 2.76±0.27 <![CDATA[0.20±0.14 &# > Comparative example 4 group 3.88±0.19 <![CDATA[0.74±0.11 &# > 2.69±0.20 <![CDATA[0.22±0.07 ## > Comparative example 5 group 3.55±0.21 <![CDATA[0.68±0.18 &# > 2.87±0.28 <![CDATA[0.20±0.05 &# > Comparative example 6 group 3.57±0.18 <![CDATA[0.69±0.12 &# > 2.85±0.31 <![CDATA[0.19±0.06 &# >

[0098] Note: Compared with the control group, between each sample-administered group & indicates P < 0.05, && indicates P < 0.01; compared with the group of Example 3, between each sample-administered group # indicates P < 0.05, ## indicates P < 0.01.

[0099] It can be seen from the above results that compared with the control group, after administration of the sample, the contents of serum TG and LDL-C can be significantly reduced; but the effects of Examples 1 - 3 are significantly better than those of each comparative example. The formulated samples of Examples 1 - 3 of the present invention have a better regulatory effect on the blood lipids of aging mice.

[0100] (7) Effects on the Contents of UREA, CREA, TNF-α, and MDA

[0101] After intragastric administration of the formulated sample to mice for 35 days, blood was collected after fasting, and the levels of serum renal function indices serum urea nitrogen (UREA) and creatinine (CREA) were detected using an automatic biochemical analyzer. After continuously intragastric administration of the formulated sample to senile mice for 35 days, blood was collected from the inner canthus of the mouse orbit, left to stand at room temperature for 2 hours, centrifuged at 1000 g and 4 °C for 15 minutes, the serum sample was aspirated, stored at -20 °C, and the levels of tumor necrosis factor (TNF-α) and malondialdehyde (MDA) in the serum sample were detected using an ELISA kit. The results are shown in the following table.

[0102] Table 9: Effects on the Contents of UREA, CREA, TNF-α, and MDA

[0103]

[0104] Note: Compared with the control group, between each sample-administered group & indicates P < 0.05, && indicates P < 0.01; compared with the sample of Example 3, between each sample-administered group # indicates P < 0.05, ## indicates P < 0.01.

[0105] It can be seen from the results that after administration of the formulated sample, compared with the control group (Ctrl), the contents of CREA and UREA in each sample-administered group were significantly reduced. However, compared with Example 3, the effects of the samples of Examples 1 - 3 were better than those of the samples of Comparative Examples 1 - 6, indicating that the formulated sample of the present invention has a better protective effect on renal injury in senile mice. Compared with the control group (Ctrl), each sample-administered group significantly reduced the serum TNF-α level and MDA level. However, compared with Example 3, the effects of the samples of Examples 1 - 3 were better than those of the samples of Comparative Examples 1 - 6, indicating that the formulated sample of the present invention shows a more positive regulatory effect on the inflammatory and oxidative stress markers in the serum of senile mice and has a better anti-aging effect.

[0106] (8) Effects on the Visceral Index of Senile Mice

[0107] After weighing and sacrificing at the end of the experimental period, the liver, kidney, spleen, and brain were removed and weighed respectively, and the visceral index was calculated according to the formula visceral index (BW%) = visceral weight (mg) / mouse body weight (g). The results are shown in the following table.

[0108] Table 10: Effects on the Visceral Index of Senile Mice

[0109]

[0110]

[0111] The visceral index is usually related to organ function and metabolic health. After continuously intragastrically administering the formulated sample to aging mice, the corresponding visceral index was calculated by dissecting and weighing each visceral organ. From the results, it can be seen that the formulated sample had no significant effect on the liver, kidney, spleen, and brain indices of aging mice. This result suggests that the formulated sample may have a neutral or positive effect on maintaining the structure and function of visceral organs during the experimental period, indicating that the formulated sample has good safety.

[0112] The experimental results show that the composition of the present invention has a positive regulatory effect on the indicators of aging mice at multiple levels. Aging is a complex process caused by multiple factors, involving oxidative stress, inflammation, metabolic disorders, and decreased immune function, etc. The composition of the embodiments of the present invention shows anti-inflammatory and antioxidant effects, reducing the levels of inflammatory mediators such as TNF-α and oxidative stress markers such as MDA; the positive regulatory effects of the composition of the embodiments of the present invention on blood lipids, liver function, and kidney function, improving muscle strength and behavior. At the same time, the composition of the embodiments of the present invention has no significant effect on the body weight and food intake of aging mice, and at the same time has no significant effect on the visceral organ index of aging mice, which indicates that long-term intake of the formulated sample will not cause malnutrition or abnormal changes in body weight, and the formulated sample has good safety and will not have a negative impact on the structure and function of visceral organs, supporting its safety as a functional food.

[0113] Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, rather than a limitation on the protection scope of the present invention. Any simple modification or equivalent replacement of the technical solution of the present invention by those of ordinary skill in the art does not depart from the essence and scope of the technical solution of the present invention.

Claims

1. An anti-aging food composition, characterized in that The raw material components of the anti-aging food composition are as follows by weight: 40-60 parts of polygonatum powder, 15-30 parts of green tea theanine, 1-3 parts of sea cucumber oligopeptide powder, 0.5-1.5 parts of spearmint extract and 0.2-0.4 parts of pyrroloquinoline quinone disodium.

2. The anti-aging food composition according to claim 1, characterized in that The raw material components of the anti-aging food composition are as follows by weight: 40-55 parts of polygonatum powder, 15-25 parts of green tea theanine, 1-3 parts of sea cucumber oligopeptide powder, 0.5-1.2 parts of spearmint extract and 0.25-0.4 parts of pyrroloquinoline quinone disodium.

3. The anti-aging food composition according to claim 1, characterized in that The raw material components of the anti-aging food composition are as follows by weight: 50 parts of polygonatum powder, 20 parts of green tea theanine, 2 parts of sea cucumber oligopeptide powder, 1 part of spearmint extract and 0.3 parts of pyrroloquinoline quinone disodium.

4. The anti-aging food composition according to any one of claims 1 to 3, characterized in that The weight ratio of the polygonatum sibiricum powder to the green tea theanine is 1-3:

1.

5. The anti-aging food composition according to any one of claims 1 to 3, characterized in that: The weight ratio of the sea cucumber oligopeptide powder, spearmint extract and pyrroloquinoline quinone disodium is 5-8:3-4:

1.

6. A method for preparing the anti-aging food composition according to any one of claims 1 to 5, characterized in that: The preparation method is as follows: weigh each raw material component according to weight, mix them evenly, and obtain the product.

7. A preparation, characterized in that The preparation comprises the anti-aging food composition according to any one of claims 1 to 5 or the anti-aging food composition prepared by the preparation method according to claim 6.

8. The preparation according to claim 7, characterized in that The preparation further comprises a food-acceptable auxiliary material, wherein the auxiliary material is selected from one or more of microcrystalline cellulose, hydroxypropyl cellulose and magnesium stearate, and the preparation is a solid beverage, a liquid beverage, a nutrition bar, a compressed candy, a pill, or a baked product.

9. Use of the anti-aging food composition according to any one of claims 1 to 5, the anti-aging food composition obtained by the preparation method according to claim 6, or the preparation according to any one of claims 7 to 8 in the preparation of anti-aging products.

10. The use according to claim 9, characterized in that: The product is a health product, functional food or special medical food.

Images